News
GSK
32.63
-1.41%
-0.47
How Might Markets React To December Inflation Report
Seeking Alpha · 12h ago
M&A Snapshot: GSK to acquire IDRx in $1.15B deal, expanding in GI cancer therapy
Seeking Alpha · 12h ago
Deals of the day-Mergers and acquisitions
Reuters · 13h ago
GSK to acquire IDRx for $1B upfront
TipRanks · 14h ago
Illumina launches pilot proteomics program with UK Biobank, collaborators
TipRanks · 14h ago
Weekly Report: what happened at GSK last week (0106-0110)?
Weekly Report · 15h ago
GSK to buy Boston-based IDRx for $1.15 billion
Seeking Alpha · 17h ago
UPDATE 1-GSK to buy US biotech firm IDRx for up to $1.15 billion
Reuters · 17h ago
GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC.
Reuters · 17h ago
Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?
Seeking Alpha · 2d ago
Key deals this week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and more
Seeking Alpha · 2d ago
Kepler Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)
TipRanks · 2d ago
GSK’s Shingrix new prefilled syringe presentation accepted for review by FDA
TipRanks · 3d ago
GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank
TipRanks · 3d ago
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
Barchart · 3d ago
Drugmakers Raise the Prices on 583 Products to Start 2025
TipRanks · 4d ago
Pharma companies welcome new year with 583 drug price hikes so far
Seeking Alpha · 4d ago
Drugs not selected for Medicare price negotiation nearly doubled - report
Seeking Alpha · 4d ago
PRESS DIGEST-British Business - Jan 9
Reuters · 4d ago
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
More
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.